Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

AB183. Therapeutic effects of adipose-derived stem cells-based micro-tissues on erectile dysfunction in streptozotocin-induced diabetic rats

Laboratory Study on Chronic Inflammation, published in Transl Androl Urol (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Transl Androl Urol (2015)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC4708785

Abstract (original English)

Objective This study aimed to explore the therapeutic effects of adipose-derived stem cells (ADSCs)-based micro-tissues (MTs) on erectile dysfunction (ED) in streptozotocin (STZ) induced diabetic rats. Methods Fifty-eight 8-week-old Sprague-Dawley rats received intraperitoneal injection of STZ (60 mg/kg) and eight weeks later, the determined diabetic rats randomly got intracavernous (IC) injection of phosphate buffer solution (PBS), ADSCs and MTs. Another eight normal rats equally received IC injection of PBS. The injected cells were tracked in ADSCs and MTs groups. Four weeks after the treatment, intracavernous pressure (ICP), histopathological changes in corpus cavernosum (CC), apoptotic index and functional proteins were measured. Results MTs expressed vascular endothelial growth factor (VEGF), nerve growth factor (NGF), tissue inhibitor of metallopeptidase-1 (TIMP-1) and tumour necrosis factor-stimulated gene 6 (TSG-6). MTs had a better retention than ADSCs and MTs treatment improved ICP, neuronal nitric oxide synthase (nNOS) expression, smooth muscle and endothelial content in diabetic rats, ameliorated apoptosis and local inflammation in CC. Conclusions The results suggested that IC injection of MTs improves the erectile function and histopathological changes in STZ-induced diabetic rats and appears to be more promising than traditional ADSCs. The underlying mechanisms in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research